A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
Terminated · Phase 2 · NCT06637631
Conditions: Crohn's Disease
At a glance
- Research payments reported, 2025
- $8,106
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 105
About the trial
- Sponsor
- Sanofi
- Tested
- SAR441566 (drug), SAR441566 matching Placebo (drug)
- Dates
- Started 2024-12-10; completion 2026-10-02
- Results posted
- Not yet
This is a phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate to severe Crohn's Disease (CD). The primary objective of this study is to assess the efficacy of different doses of SAR441566 compared with placebo in participants with moderate to severe CD. This study will have an anticipated duration of up to 59 weeks which will include a screening period of 4 weeks (+7 calendar days if needed), followed by the Main Study (MS) treatment period, lasting 52 weeks, and a 2-week follow-up period after end of treatment for participants not enrolling in the Long Term Safety (L…
From ClinicalTrials.gov, last updated 2026-10-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $8,106 in research payments for this study in 2025 (34 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $8,106
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.